Valvular Heart Disease: Recommendations
See the 2014 valvular heart disease CPG for the complete set of recommendations and specific definitions of disease severity
15and Online Data Supplement 4 for additional information on valvular heart disease.
Class I
- It is recommended that patients with clinically suspected moderate or greater degrees of valvular stenosis or regurgitation undergo preoperative echocardiography if there has been either 1) no prior echocardiography within 1 year or 2) a significant change in clinical status or physical examination since last evaluation.60(Level of Evidence: C)
- For adults who meet standard indications for valvular intervention (replacement and repair) on the basis of symptoms and severity of stenosis or regurgitation, valvular intervention before elective noncardiac surgery is effective in reducing perioperative risk.15(Level of Evidence: C)
Significant valvular heart disease increases cardiac risk for patients undergoing noncardiac surgery.
37,
48 Patients with suspected valvular heart disease should undergo echocardiography to quantify the severity of stenosis or regurgitation, calculate systolic function, and estimate right heart pressures. Evaluation for concurrent CAD is also warranted, with electrocardiography exercise testing, stress echocardiographic or nuclear imaging study, or coronary angiography, as appropriate.
Emergency noncardiac surgery may occur in the presence of uncorrected significant valvular heart disease. The risk of noncardiac surgery can be minimized by 1) having an accurate diagnosis of the type and severity of valvular heart disease, 2) choosing an anesthetic approach appropriate to the valvular heart disease, and 3) considering a higher level of perioperative monitoring (eg, arterial pressure, pulmonary artery pressure, transesophageal echocardiography), as well as managing the patient postoperatively in an intensive care unit setting.
2.4.1. Aortic Stenosis: Recommendation
Class IIa
- Elevated-risk elective noncardiac surgery with appropriate intraoperative and postoperative hemodynamic monitoring is reasonable to perform in patients with asymptomatic severe aortic stenosis (AS).48,75–84(Level of Evidence: B)
In the Original Cardiac Risk Index, severe AS was associated with a perioperative mortality rate of 13%, compared with 1.6% in patients without AS.
48 The mechanism of MACE in patients with AS likely arises from the anesthetic agents and surgical stress that lead to an unfavorable hemodynamic state. The occurrence of hypotension and tachycardia can result in decreased coronary perfusion pressure, development of arrhythmias or ischemia, myocardial injury, cardiac failure, and death.
With the recent advances in anesthetic and surgical approaches, the cardiac risk in patients with significant AS undergoing noncardiac surgery has declined. In a single, tertiary-center study, patients with moderate AS (aortic valve area: 1.0 cm2 to 1.5 cm2) or severe AS (aortic valve area <1.0 cm2) undergoing nonemergency noncardiac surgery had a 30-day mortality rate of 2.1%, compared with 1.0% in propensity score–matched patients without AS (P=0.036).
75 Postoperative MI was more frequent in patients with AS than in patients without AS (3.0% versus 1.1%; P=0.001). Patients with AS had worse primary outcomes (defined as composite of 30-day mortality and postoperative MI) than did patients without AS (4.4% versus 1.7%; P=0.002 for patients with moderate AS; 5.7% versus 2.7%; P=0.02 for patients with severe AS). Predictors of 30-day death and postoperative MI in patients with moderate or severe AS include high-risk surgery (odds ratio [OR]: 7.3; 95% CI: 2.6 to 20.6), symptomatic severe AS (OR: 2.7; 95% CI: 1.1 to 7.5), coexisting moderate or severe mitral regurgitation (MR) (OR: 9.8; 95% CI: 3.1 to 20.4), and pre-existing CAD (OR: 2.7; 95% CI: 1.1 to 6.2).
For patients who meet indications for aortic valve replacement (AVR) before noncardiac surgery but are considered high risk or ineligible for surgical AVR, options include proceeding with noncardiac surgery with invasive hemodynamic monitoring and optimization of loading conditions, percutaneous aortic balloon dilation as a bridging strategy, and transcatheter aortic valve replacement (TAVR). Percutaneous aortic balloon dilation can be performed with acceptable procedural safety, with the mortality rate being 2% to 3% and the stroke rate being 1% to 2%.
76–78,
84However, recurrence and mortality rates approach 50% by 6 months after the procedure. Single-center, small case series from more than 25 years ago reported the use of percutaneous aortic balloon dilation in patients with severe AS before noncardiac surgery.
79–81 Although the results were acceptable, there were no comparison groups or long-term follow-up. The PARTNER (Placement of Aortic Transcatheter Valves) RCT demonstrated that TAVR has superior outcomes for patients who are not eligible for surgical AVR (1-year mortality rate: 30.7% for TAVR versus 50.7% for standard therapy) and similar efficacy for patients who are at high risk for surgical AVR (1-year mortality rate: 24.2% for TAVR versus 26.8% for surgical AVR).
82,
83However, there are no data for the efficacy or safety of TAVR for patients with AS who are undergoing noncardiac surgery.